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Abstract
Background: Dyslipidemia represents a significant non-infectious comorbidity among people living with HIV. The
aim of this study is to evaluate the impact on lipid profile of switches from an efavirenz (EFV) or protease inhibitor/
ritonavir (PI/r)-based regimen to a rilpivirine (RPV) or a once-daily integrase inhibitor-based regimen.
Methods: We analyzed data from SCOLTA prospective database. All patients with HIV-RNA < 50 copies/ml in
therapy with two NRTI + EFV or PI/r were included if they switched from EFV to dolutegravir (group EFV-DTG),
elvitegravir (EFV-EVG), or RPV (EFV-RPV) and from PI/r to DTG (PI/r-DTG), PI/r to EVG (PI/r-EVG), or PI/r to RPV (PI/r-RPV).
Total cholesterol (TC), TC/HDL ratio, LDL-cholesterol (LDL) and triglycerides (TG) were compared at baseline, six months
and one year. Comparisons among groups were performed by a general linear model.
Results: Four hundred and ninety patients were enrolled, 24.9% female, mean age 47.3 years (±10.1). According to ART
switch, 11.4% were classified in group EFV-DTG, 3.9% in EFV-EVG, 23.9% in EFV-RPV, 17.6% in PI/r-DTG, 17.8% in PI/r-EVG,
and 25.5% in PI/r-RPV. After adjusted analysis, TC significantly decreased in all groups but EFV-EVG, TC/HDL in all but
EFV-DTG and EFV-EVG, while the reduction of TG was significant only in switches to RPV (EFV-RPV and PI/r-RPV). The
one year decrease of TC, TC/HDL, LDL and TG was higher in patients with higher baseline levels of the same variable
(p < .0001 for all).
Conclusions: In SCOLTA, all switches from PI/r regimens gave advantages on lipid profile, while stopping EFV had
consistently favorable lipid effects only if replaced by RPV.
Keywords: Dyslipidemia, Rilpivirine, Integrase inhibitors, Cholesterol, Framingham risk score
* Correspondence: taramasso.lucia@gmail.com
†Lucia Taramasso and Paola Tatarelli contributed equally to this work.
1Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy
2Infectious Diseases Unit, Department of Internal Medicine, Fondazione
IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Taramasso et al. BMC Infectious Diseases  (2018) 18:357 
https://doi.org/10.1186/s12879-018-3268-5
Background
Cardiovascular disease represents a significant non-in-
fectious comorbidity among people living with HIV in
the era of modern antiretroviral therapy (ART) [1].
Dyslipidemia, a well-known cardiovascular risk factor,
is frequent and undertreated in this setting [2, 3],
where it finds a multi-factorial pathogenesis including
host factors, pro-atherogenic HIV action and drug
toxicity [4]. Available antiretroviral drugs might favor
weight gain, and show variable effects on lipids, with
relevant differences both among classes and within the
same class [5]. Nucleoside reverse transcriptase inhibitors
(NRTIs) do not adversely affect lipids, with tenofovir
(TDF) showing a modest lipid-lowering effect [6]. Among
non-NRTIs, nevirapine and rilpivirine (RPV) have an
overall favorable lipid profile compared to efavirenz (EFV)
[7, 8]. Ritonavir-boosted protease inhibitors (PI/r) are glo-
bally associated with hypercholesterolemia and hypertri-
glyceridemia, even if these effects vary with the individual
PI/r [9]. Integrase strand transfer inhibitors (INSTIs), es-
pecially cobicistat-free ones, have neutral impact on lipids
[10, 11]. Nowadays, minimizing drug-related toxicity and
improving ART adherence are the main goals of simplifi-
cation strategies in HIV-suppressed patients. Favorable
effects on lipid profile are expected in patients switching
to a lipid-friendly, once-daily currently available regimen.
However, little is known about the achievement of these
expectations in real-life experiences. The aim of this study
is to evaluate the impact on lipid profile of a switch from
an EFV or PI/r-based regimen to a RPV or a once-daily
INSTI-based regimen in a prospective observational co-
hort of HIV-infected individuals.
Methods
The SCOLTA (Surveillance Cohort Long-Term Toxicity
Antiretrovirals) project is a multicentre observational
study started in 2002 that follows HIV-infected people
who start a new drug prospectively with the aim of iden-
tifying toxicities and adverse events in real life setting
[12]. Both ART naïve and experienced patients can be
included in the SCOLTA cohort, if they are > 18 years
and agree study entry. Demographic, clinical and labora-
tory data, including total cholesterol (TC), HDL choles-
terol (HDL), LDL-cholesterol (LDL) and triglycerides
(TG), are prospectively collected in anonymous form in
a central database every six months, while adverse
events and treatment interruptions are recorded at the
moment in which they occur [12]. We performed a
query to this prospectively collected database including
patients enrolled from its beginning until September
2017 (date of data extraction). We considered all pa-
tients in therapy with 2 NRTI associated either to EFV
or to PI/r. Patients were enrolled in the study if they had
undetectable HIV-RNA (< 50 copies/ml) for at least six
months and switched from EFV to dolutegravir (DTG,
group EFV-DTG), elvitegravir (EVG, group EFV-EVG),
or RPV (group EFV-RPV) or from PI/r to DTG (group
PI/r-DTG), EVG (group PI/r-EVG) or RPV (group PI/
r-RPV). Patients switched to EVG have been enrolled
from July 2012 to December 2016, patients in RPV from
February 2013 to December 2016 and patients in DTG
from July 2012 to September 2017. Values of TC, HDL,
TC/HDL ratio, LDL and TG were compared at baseline,
six months (T1) and one year (T2) after the switch. Car-
diovascular risk at baseline and T2 was assessed using the
Framingham Risk Sore [13], as this algorithm showed a
good predictive value in a real-life Italian cohort of HIV
infected patients [14]. The study protocol of the SCOLTA
Group was approved by local ethical committees and con-
ducted in accordance with the ethical principles stated in
the Declaration of Helsinki. Written consent was obtained
from all participants.
Patients were described using frequency for categorical
variables and mean (standard deviation, SD) or median
(interquartile range, IQR) for continuous variables.
Comparisons of TC, HDL, TC/HDL, LDL and TG varia-
tions in different switch groups were performed at T1
and T2 by GLM least square means procedure, and ad-
justed for age, sex, years on ART, diabetes, statin use and
baseline levels of each variable at multivariable analysis.
The analyses among groups were adjusted for multiple
comparisons between groups (Sidak correction). Differ-
ences were considered significant for p values < 0.05.
Results
During the study period 490 patients satisfied the inclu-
sion criteria and were enrolled. In this population, 122
patients were female (24.9%), the mean age was 47.3 years
(±10.1) and mean CD4+ T-cell count 653 (±345) cells/μl.
Two-hundred-fifty-four patients (51.8%) were in CDC
stage A, 142 (29.0%) in B, and 94 (19.2%) in C. According
to the type of ART switch, 56 (11.4%) patients were classi-
fied as group EFV-DTG, 19 (3.9%) EFV-EVG, 117 (23.9%)
EFV-RPV, 86 (17.6%) PI/r-DTG, 87 (17.8%) PI/r-EVG, and
125 (25.5%) PI/r-RPV. Median cumulative time on ART,
expressed in years, was 12.2 (IQR 8.2–17.1) in EFV-DTG,
5.9 (4.7–11.0) in EVF-EVG, 6.0 (3.0–10.8) in EFV-RPV,
10.4 (5.0–17.1) in PI/r-DTG, 8.1 (2.1–16.7) in PI/r-EVG
and 4.6 (2.0–11.4) in PI/r-RPV. At baseline, diabetes was
recorded for 23 patients (4.7%), equally distributed among
study groups (p = .1); 47 (9.6%) patients were in therapy
with statin and 5 (1.0%) with fibrates. Baseline values of
the lipid variables and Framingham risk score are shown
in Table 1. During the follow-up, 12 (2.4%) patients started
a new treatment with statin, while 6 (1.2%) stopped the
statin they were already taking. No patients started or
stopped fibrate use during the study.
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Figure 1 shows the trend of the lipid variables across
the study, as well as the number of available observa-
tions for each one. The frequencies of patients with TC
under the standard target level of 190 mg/dl counseled
by European AIDS Society guidelines [15] were 43.4%
(209/482 patients) at baseline, 59.6% (274/469 patients)
at T1 and 60.3% (208/345 patients) at T2. Differences
found in TC, HDL, TC/HDL, LDL and TG at T2 were
examined after adjustment for age, sex, use of statin, dia-
betes, years of ART and baseline level of each analyzed
variable. Results of multivariable analysis at T2 are sum-
marized in Tables 2 and 3.
Total cholesterol
All patients but EFV-EVG group had significant TC de-
crease at T2. TC trend in EFV-EVG was significantly dif-
ferent to that of EFV-RPV (p = .0013), but in all other
comparisons the inter-groups differences were not sig-
nificant. Patients with higher baseline TC experienced
the higher TC decrease after the switch (p < .0001), while
sex, age, years on ART and statin use had no influence.
HDL-cholesterol
Mean HDL changed differently in different switch groups
(p = .0002), rising in EFV-EVG, PI/r-DTG and PI/r-EVG,
while decreasing in EFV-DTG, EFV-RPV and PI/r-RPV.
The HDL variations in each group resulted not significant
after adjustment, when compared to baseline levels, with
the exception of group EFV-RPV, in which the mean HDL
decrease of − 4.1 mg/dl was significant (p = .0421). HDL
variations were also linked to sex (HDL increased in
women as compared to men, p = 0.0067) and baseline
levels (p < .0001), as HDL decrease was more marked in
patients with higher baseline level. Age, years on ART and
statin use did not influence HDL changes.
TC/HDL ratio
Mean TC/HLD decreased significantly in all switches
from PI/r (group PI/r-DTG, p = .0015; group PI/r-EVG,
p = .0007; group PI/r-RPV, p = .0021), while switches
from EFV gave significant changes only in RPV group
(group EVF-RPV, p = .0021). A higher decrease was also
found in patients with higher baseline TC/HDL ratio
(p < .0001), while no differences were found on the basis
of sex, statin use, age and different type of switches after
multiple comparisons.
LDL cholesterol
LDL decreased significantly only for switches to RPV
(groups EFV-RPV and PI/r-RPV, p < .0001 and p = 0.0064,
respectively) and in the switch from PI/r to EVG (group
PI/r-EVG, p = .0312). However, the inter-groups differ-
ences resulted not significant after adjustment for multiple
comparisons, as well as sex, age, years on ART and statin
use. Higher baseline LDL levels were instead linked to
significant decreases at T2 (p < .0001).
Triglycerides
The mean TG decrease at T2 was statistically significant
only for switches to RPV containing regimes (groups
EFV-RPV and PI/r-RPV; p = .0116 and p = .0216, respect-
ively). Multiple comparisons did not find significant
inter-groups differences. Patients with higher baseline values
were more likely to experience significant TG decreases
(p < .0001), independently of sex, age and use of statins.
Framingham risk score
Framingham risk score was calculated for 294 and 187
patients at baseline and T2 (both using the baseline age),
respectively. It did not change significantly in any
groups. Patients with higher baseline levels experienced
the highest risk score reductions, even if not statistically
significant and not consistently linear: patients with
baseline FRS < 10.0 showed an increase of 0.1, those with
intermediate risk a reduction of 1.0, and those at high
risk (FRS ≥ 20.0) a reduction of 0.3 (p = 0.20). Risk score
changes in different groups of switches remained
non-significant also after adjustment for baseline Fra-
mingham risk score and statin use (Table 2).
Table 1 Baseline levels of total cholesterol (TC), HDL cholesterol (HDL), LDL cholesterol (LDL), TC/HDL ratio, triglycerides (TG) and
Framingham score (FRS) across groups. Variable are expressed as means (±SD) or medians (Q1-Q3)
Variable Switches from 2NRTI + EFV to Switches from 2NRTI + PI/r to
DTG EVG RPV DTG EVG RPV
TC (mg/dl) 198.5 (41.6) 207.4 (40.7) 196.5 (38.0) 209.9 (41.0) 203.7 (43.9) 189.2 (47.1)
HDL (mg/dl) 53.5 (16.7) 49.3 (14.4) 48.8 (13.8) 48.8 (14.7) 43.5 (12.3) 48.8 (21.0)
TC/HDL (mg/dl) 3.93 (1.1) 4.4 (1.1) 4.3 (1.4) 4.65 (1.6) 4.98 (1.6) 4.2 (1.3)
LDL (mg/dl) 117.0 (39.4) 128.2 (32.6) 120.3 (35.5) 126.0 (33.7) 123.5 (38.2) 111.1 (39.5)
TG (mg/dl) 114 (91.5–153.5) 126.5 (106–171) 109 (77–160) 142 (84–215) 150 (112–204) 117 (85–189)
FRS (%) 12.2 (6.7–25.3) 6.7 (3.9–9.4) 7.9 (4.7–13.2) 9.4 (4.5–21.6) 9.4 (4.5–15.6) 7.3 (3.3–13.2)
NRTI nucleoside reverse transcriptase inhibitors, EFV efavirenz, PI/r ritonavir-boosted protease inhibitors, DTG dolutegravir, EVG elvitegravir, RPV rilpivirine
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Diabetic patients
With the limit of the low number of diabetic patients in-
cluded in the study (n = 23, 4.7%), we analyzed lipid
changes from baseline in this category. We did not find
significant differences in those who switched from EFV
to any regimens, while diabetic patients who switched
from PI/r had significant improvements in lipid profile
as compared to non-diabetic patients (TC, − 66.0 vs − 11.0,
p = 0.0002;; TC/HDL ratio − 1.8 vs − 0.38, p < 0.0001;
LDL-C -42.2 vs − 4.6, p = 0.01).
Fig. 1 Mean variations of total cholesterol (TC), HDL cholesterol (HDL), TC/HDL ratio, LDL cholesterol (LDL) and median variation of triglycerides
(TG) from baseline (BL), to 6 and 12 months of follow up (T1 and T2, respectively) for each switch group (A-F). Tables below each graph show the
number of observations at each time-point. Only patients with observations at T1 or T1/T2 are considered in the graph. A: switch from 2
nucleoside reverse transcriptase inhibitors (NRTI) + efavirenz to 2NRTI + dolutegrvir; B: switch from 2NRTI + efavirenz to 2NRTI + elvitegravir; C: switch
from 2NRTI + efavirenz to 2NRTI + rilpivirine; D: switch from 2NRTI + protease inhibitors to 2NRTI + dolutegravir; E: switch from 2NRTI + protease
inhibitors to 2NRTI + elvitegravir; D: switch from 2NRTI + protease inhibitors to 2NRTI + rilpivirine
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TDF containing regimens
Finally, we run a model including also information on TDF
use, in both initial and post-switch regimens: the results of
the primary analyses were confirmed. Three-hundred and
seventy-seven (76.9%) patients were on TDF before
and 365 (74.5%) after the switch. In both patients
who were initially treated with TDF and those who were
not, all the variables showed the same trends described in
the general population.
Treatment failure
Forty-four patients discontinued or changed their ther-
apy before T2, for either clinical reasons or patients’ per-
sonal choices. Thirty-two patients experienced at least
one detectable HIV-RNA during the follow-up (7 at T1,
18 at T2, 7 both at T1 and T2), with HIV-RNA > 200
copies/ml in 11 cases, of whom 7 had HIV-RNA > 1000
copies/ml.
Discussion
Here we present the changes of lipid parameters at
12 months of follow-up in a prospective cohort of
HIV-infected patients switching from an EFV or PI/
r-based regimen to a RPV or a once-daily INSTI-based
regimen. We found that replacing PI/r gives advantages
on both TC and TC/HDL ratio regardless of the switch
group (to DTG, EVG or RPV) and that in case of switch
to RPV these advantages extend also on TG and LDL.
Also, EFV interruption has a favourable effect on all the
studied parameters only if replaced by RPV. These find-
ings suggest that, among the analysed antiretroviral
switches, the most favourable lipid impact is obtained
by replacing PI/r and EFV with RPV, but significant
advantages can also be obtained by replacing PI/r with
once-daily INSTI regimens. Other published studies found
that switching to RPV-containing regimens leads to an
improvement of lipid profile, with some differences
among the analysed variables. The SPIRIT study, a ran-
domized clinical trial on safety and efficacy of switching
from a PI-based regimen to TDF/emtricitabine (FTC)/
RPV in virologically suppressed patients, found significant
improvements in TC, LDL, TG and TC/HDL ratio in the
immediate switch arm compared with the delayed switch
arm [16]. In a multicentre, retrospective study, Pinetti et
al. analysed efficacy and safety of treatment simplification
to RPV/FTC/TDF in a real-life setting. They found that
both TC and TG significantly decreased in patients
switching from PI-based regimens, while only TC
Table 2 Adjusted mean difference from baseline (mean) and standard error (SE) of total cholesterol (TC), LDL-cholesterol (LDL), total
cholesterol/HDL-cholesterol ratio (TC/HDL) and triglycerides (TG) one year after the switch
Switch TC T2 - TC T0
(mg/dl)
LDL T2 - LDL T0
(mg/dl)
HDL T2 - HDL T0
(mg/dl)
TC/HDL T2 - TC/HDL
T0
(mg/dl)
TG T2 - TG T0
(mg/dl)
FRS T2 - FRS T0
From To mean (±SE) p* mean (±SE) p* mean (±SE) p* mean (±SE) p* mean (±SE) p* mean (±SE) p§
2 NRTI + EFV DTG −15.0 ± 6.5 .0210 − 10.9 ± 6.2 .0771 −1.4 ± 1.8 .4222 − 0.21 ± 0.21 .3242 − 19.6 ± 15.2 .1992 0.67 ± 0.71 0.35
EVG 1.7 ± 8.6 .8401 − 5.9 ± 8.0 .4623 2.8 ± 2.4 .2350 − 0.32 ± 0.27 .2488 27.2 ± 20.5 .1853 0.74 ± 0.92 0.42
RPV −31.6 ± 5.3 <.0001 −21.0 ± 5.0 <.0001 − 2.9 ± 1.4 .0421 − 0.52 ± 0.17 .0021 −31.5 ± 12.4 .0116 0.03 ± 0.38 0.93
2 NRTI + PI/r DTG −16.8 ± 5.9 .0049 −8.8 ± 5.7 .1247 2.4 ± 1.6 .1335 − 0.60 ± 0.19 .0015 −26.1 ± 14.0 .0628 − 0.54 ± 0.60 0.36
EVG −16.6 ± 5.8 .0044 − 12.0 ± 5.6 .0312 3.0 ± 1.6 .0604 − 0.63 ± 0.18 .0007 −23.0 ± 16.6 .0926 −0.87 ± 0.52 0.10
RPV − 20.7 ± 5.2 <.0001 −13.6 ± 5.0 .0064 0.00 ± 1.4 .9995 − 0.52 ± 0.17 .0021 − 28.2 ± 12.2 .0216 −0.25 ± 0.48 0.60
NRTI nucleoside reverse transcriptase inhibitors; EFV efavirenz, PI/r ritonavir-boosted protease inhibitors, DTG dolutegravir, EVG elvitegravir, RPV rilpivirine, T0
baseline, T2 one year follow up. Significant p values (p < 0.05) are indicated by bold font
*Adjustment for age, sex, baseline value of the analyzed variable, time on antiretroviral therapy, diabetes and use of statin
§ Adjustment for baseline value of FRS and time on antiretroviral therapy
Table 3 Covariate analysis of total cholesterol (TC), HDL-cholesterol (HDL), TC/HDL ratio, LDL-cholesterol (LDL), tryglicerides (TG) and
Framingham risk score (FRS), according to confounding factors used in the multivariable analysis: all confounders and treatment
groups were included at the same time
TC HDL TC/HDL LDL TG FRS
Age (b-value, by 1) 0.3 p = 0.09 0.0 P = 0.92 0.0 P = 0.45 0.27 P = 0.10 0.1 P = 0.89 –
Sex (b-value, F vs M) 6.6 P = 0.10 3.4 P = 0.007 −0.24 P = 0.07 1.7 P = 0.65 2.8 P = 0.77 –
Diabetes (b-value, Y vs N) −9.7 P = 0.22 0.9 P = 0.68 −0.3 P = 0.24 −7.4 P = 0.34 14.5 P = 0.43 –
Statins (b-value, Y vs N) −10.1 P = 0.08 −1.3 P = 0.41 −0.0 P = 0.66 −7.8 P = 0.15 1.1 P = 0.93 −0.35 0.62
ART duration (b-value, by 1) −0.2 P = 0.34 −0.1 P = 0.37 − 0.0 P = 0.86 −0.0 P = 0.84 − 0.4 P = 0.52 0.02 P = 0.58
Baseline value (b-value, by 1) − 0.4 P < 0.0001 −0.3 P < 0.0001 − 0.43 P < 0.0001 −0.43 P < 0.0001 − 0.5 p < 0.0001 −0.02 P = 0.32
F female, M male, Y yes, N no, ART antiretroviral therapy
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significantly decreased in patients switching from NNRTI
[17]. A significant decrease in TC has also been described
in switches from unboosted PIs to RPV [18]. Finally, in a
recent study Gagliardini et al. described a significant TC
and HDL reduction at one, two and three-year follow-up
after switching from EFV/FTC/TDF to RVP/FTC/TDF,
while LDL and TG improvement was observed only up to
two-year follow-up and no difference was found in TC/
HDL ratio over time [19].
In our study, favourable lipids effects were also found
in patients switching from boosted PI to DTG or EVG.
Two clinical trials on switch from PI to DTG previously
reported similar results in both patients with Framingham
risk score > 10%, that experienced TC, TC/HDL, LDL and
TG significant decrease [20], and in patients with any car-
diovascular risk scores, that had TC and TG significantly
lower and HDL significantly higher if switched to DTG,
compared to patients who continued PIs [21]. In contrast,
total cholesterol did not decrease in patients switching
from any triple ART to ABC/3TC/DTG in a double-blind
randomized trial [22]. Favorable effects on lipids have also
been reported in switches to EVG. In the STRATEGY-PI
clinical trial patients switching from lopinavir (but not
from atazanavir) to TDF/FTC/cobicistat(C)/EVG obtained
significant TC decline after 96 weeks [23] and the same
was also seen in the SRTATEGY-NNRTI trial in patients
switching from EFV to TDF/FTC/C/EVG, although with-
out significant changes in TC/HDL ratio [24]. It has been
widely demonstrated that TG/HDL ratio correlates with
insulin resistance [25]. Interestingly, in our study only pa-
tients switching from PI/r to DTG or EVG (groups D and
E) reached the desired outcome of higher HDL and lower
TG, that is related to lower insulin resistance [26], while
in all the other groups the trend of HDL had the same dir-
ection as that of TG. This result suggests that a favorable
effect on insulin resistance could be achieved with the
withdrawal of the PI/r, a drug class with possible implica-
tions in insulin resistance [27]. One of the most interest-
ing finding of our study is that the greater effect on lipids,
in switches to once-daily INSTI- or RPV-based regimens,
was obtained in patients with higher baseline values of
each variable (p < .0001 for all) and in diabetic patients as
compared to non diabetic ones. This result highlights the
importance of ART optimization with low-metabolic
impact-regimens especially in patients who have the high-
est need of lipid control, that are exactly the ones who
achieve better outcomes. Current guidelines [15, 28] do
not provide indications for type of ART switch in case of
dyslipidemia, also if dyslipidemia is mentioned as an
adverse event for both EFV, and PI/r and both INSTI
and RPV are considered drugs with lower impact on
lipids [15, 28]. In Italian guidelines, in the setting of high
cardiovascular risk, it is suggested to substitute PI/r with
NNRTIs, or with other PIs with lower metabolic impact
or with raltegravir [29, 30]. We think that the present
study should suggest that, in HIV-infected patients with
high cardiovascular risk and who are treated with PI/r or
EFV, a switch to RPV or INSTI should be considered.
However, ART switch alone is not enough to significantly
change the risk of cardiovascular event in HIV-infected
patients, as demonstrated by the lack of significant change
of the Framingham risk score across time in our series.
Although our results encourage switching ART in patients
with high cholesterol or triglycerides levels, lifestyle inter-
ventions and lipid lowering agents prescription remain
keystones for the prevention of cardiovascular disease,
and cannot be fully substituted by a switch strategy.
Finally, a low number of virological failures is observed
in this study, pointing out that a careful evaluation of
patients’ characteristics, historical HIV genotype and
drug-drug interactions should always have the priority
before planning any therapeutic modifications.
The present study has some limitations. Despite the
prospective data collection, the cohorts of patients with
different antiretroviral therapies have been enrolled at
different times and the study was purely observational.
Thus, it is possible that the choice of ART regimen was
guided by different patients’ characteristics that may
have influenced the results of the analysis, and that the
reasons that have guided the decision of starting each
single regimen in different study groups have played a
confounding role in the analysis. For the same reason,
we do not have a randomized control group and cannot
demonstrate the causality between ART switch and the
measured outcomes. Moreover, lifestyle interventions
during follow up have not been registered, and thus we
cannot estimate their impact on the study outcomes.
Conclusions
In our study, in a large cohort of patients prospectively
followed up in a real-life context, we found significant
improvements of TC and TC/HDL levels in switches from
PI/r to the modern once daily INSTI-based therapies and
also on LDL in the switch from PI/r to EVG.
Both switches from PI/r and EFV-based therapies to
RPV gave advantages in terms of TC, TC/HDL and also
TG and LDL values.
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